优化Baveno VII标准诊断临床显著门脉高压:个体患者数据荟萃分析
该系统综述与荟萃分析纳入5项研究共1433例代偿期进展性慢性肝病患者,验证Baveno VII标准诊断临床显著门脉高压(CSPH)的性能。LSM≥25 kPa的总体阳性预测值为92%,但在肥胖合并MASLD患者中降低;采用ANTICIPATE ± NASH模型≥75%风险阈值可将阳性预测值提高至95%,包括肥胖MASLD患者(从0.67升至0.83,p<0.001)。排除标准的汇总阴性预测值为99%。
要点
- Baveno VII标准在多数病因中准确诊断CSPH,但肥胖MASLD患者阳性预测值降低
- ANTICIPATE ± NASH模型≥75%风险阈值提高阳性预测值至95%
- 排除标准(LSM≤15 kPa且血小板≥150×10⁹/L)阴性预测值达99%
核心结论
- Baveno VII标准可准确分类不同病因的CSPH,但在肥胖合并MASLD患者中性能降低。
- 采用ANTICIPATE ± NASH模型≥75%风险阈值可提高诊断准确性,尤其在肥胖MASLD患者中。
研究设计与样本
- 系统综述与个体患者数据荟萃分析,检索Baveno VII共识发布至2024年6月。
- 纳入5项验证Baveno VII标准的研究,共1433例代偿期进展性慢性肝病患者,以肝静脉压力梯度为参考标准。
主要发现
- LSM≥25 kPa的汇总阳性预测值为92%,但在肥胖MASLD患者中降低。
- ANTICIPATE ± NASH模型≥75%风险阈值使阳性预测值提高至95%,肥胖MASLD患者从0.67升至0.83(p<0.001)。
- 排除标准(LSM≤15 kPa且血小板≥150×10⁹/L)的汇总阴性预测值为99%。
- ANTICIPATE ± NASH模型在各中心表现一致。
关键数值与推荐
- 纳入标准:LSM≥25 kPa,汇总阳性预测值92%。
- 排除标准:LSM≤15 kPa且血小板计数≥150×10⁹/L,汇总阴性预测值99%。
- ANTICIPATE ± NASH模型≥75%风险阈值,阳性预测值95%。
临床怎么用
- Baveno VII标准可用于排除和确认CSPH,但肥胖MASLD患者需谨慎。
- 可基于BMI、肝硬度值和血小板计数通过在线计算器应用ANTICIPATE ± NASH模型≥75%阈值识别CSPH。
- 有助于筛选适合预防性β受体阻滞剂治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) has major therapeutic implications. CSPH can be assessed using the Baveno VII criteria, though performance is reduced in patients with obesity (BMI ≥30 kg/m2) and metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to validate the Baveno VII criteria and refine them using the ANTICIPATE ± NASH models. METHODS: We conducted a systematic review of studies validating the Baveno VII criteria for diagnosing CSPH, using hepatic venous pressure gradient as the reference standard. A search combining "CSPH" AND "Baveno VII" was performed from the Baveno VII consensus publication until June 2024. A meta-analysis evaluated the rule-in criterion (liver stiffness measurement [LSM] ≥25 kPa) and rule-out criterion (LSM ≤15 kPa + platelet count ≥150 × 109/L). We also assessed whether applying a ≥90% positive predictive value (PPV) risk threshold for CSPH, as predicted by ANTICIPATE ± NASH, improved diagnostic performance. Individual patient data were analyzed to evaluate model performance by center. RESULTS: Five studies including 1,433 patients with cACLD (CSPH prevalence 34-62%) of various etiologies were identified. The rule-in threshold of LSM ≥25 kPa achieved an overall pooled PPV of 92% across etiologies, except in MASLD with obesity. Applying a ≥75% CSPH risk threshold from the ANTICIPATE ± NASH models increased the PPV to 95%, including among patients with MASLD and obesity (PPV improved from 0.67 to 0.83; p <0.001). The pooled negative predictive value for the rule-out criterion was 99% across all etiologies. ANTICIPATE ± NASH models performed consistently well across centers. CONCLUSION: The Baveno VII criteria accurately classify CSPH across etiologies, except in MASLD with obesity. Incorporating a ≥75% risk threshold from the ANTICIPATE ± NASH models enhances diagnostic accuracy, particularly in MASLD with obesity, and may provide a simpler approach for identifying CSPH in clinical practice. IMPACT AND IMPLICATIONS: This systematic review and meta-analysis confirm the validity of the Baveno VII criteria for both ruling out and ruling in clinically significant portal hypertension in patients with compensated advanced chronic liver disease. Applying a ≥75% risk threshold from the ANTICIPATE ± NASH models further improves overall diagnostic performance across etiologies. This provides a practical and accessible approach for hepatologists to identify candidates for prophylactic β-blocker therapy, as the calculation is based on simple clinical parameters - body mass index, liver stiffness, and platelet count - using an online calculator.
引用
- Bañares J, Pons M, Reiberger T, et al. Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis. J Hepatol. 2025. PMID: 41138818. doi:10.1016/j.jhep.2025.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。